141 related articles for article (PubMed ID: 37568763)
41. Home-based multidimensional survivorship programmes for breast cancer survivors.
Cheng KKF; Lim YTE; Koh ZM; Tam WWS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011152. PubMed ID: 28836379
[TBL] [Abstract][Full Text] [Related]
42. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
43. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
[TBL] [Abstract][Full Text] [Related]
44. Patient-centered Outcomes in Breast Cancer: Description of EQ-5D-5L and EORTC-QLQ-BR23 Measurements in Real-world Data and Their Association With Survival.
Monteiro MR; Nunes NCC; Crespo J; Abrahão ABK; Buscacio G; Lerner LCC; Sermoud L; Arakelian R; Piotto G; Lemos C; Campos R; Victorino D; Andrade PM; Ferreira TAV; Pecoraro JP; Meton F; Gaui MF; Araujo LH
Clin Oncol (R Coll Radiol); 2022 Sep; 34(9):608-616. PubMed ID: 35667940
[TBL] [Abstract][Full Text] [Related]
45. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
46. [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
Yan X; An N; Jiang GQ; Gao M; Gao YN
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):298-301. PubMed ID: 18788637
[TBL] [Abstract][Full Text] [Related]
47. Minilaparotomy, Cyfra21-1, and Other Predicting Factors for Suboptimal Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer: A Pilot Study.
Nantasupha C; Pojchamarnwiputh S; Charoenkwan K
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4119-4124. PubMed ID: 36579993
[TBL] [Abstract][Full Text] [Related]
48. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Cancer; 1995 Nov; 76(9):1606-14. PubMed ID: 8635065
[TBL] [Abstract][Full Text] [Related]
49. A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
Chesnais M; Lecuru F; Mimouni M; Ngo C; Fauconnier A; Huchon C
PLoS One; 2017; 12(11):e0187245. PubMed ID: 29117194
[TBL] [Abstract][Full Text] [Related]
50. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.
Osoba D; Zee B; Pater J; Warr D; Kaizer L; Latreille J
Qual Life Res; 1994 Oct; 3(5):353-64. PubMed ID: 7841968
[TBL] [Abstract][Full Text] [Related]
51. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
52. Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study.
Szczesny W; Langseth H; Myklebust TÅ; Kaern J; Tropé C; Paulsen T
Acta Obstet Gynecol Scand; 2018 Aug; 97(8):956-965. PubMed ID: 29790149
[TBL] [Abstract][Full Text] [Related]
53. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes.
Catto JWF; Downing A; Mason S; Wright P; Absolom K; Bottomley S; Hounsome L; Hussain S; Varughese M; Raw C; Kelly P; Glaser AW
Eur Urol; 2021 May; 79(5):621-632. PubMed ID: 33581875
[TBL] [Abstract][Full Text] [Related]
54. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study.
Miralpeix E; Sole-Sedeno JM; Rodriguez-Cosmen C; Taus A; Muns MD; Fabregó B; Mancebo G
World J Surg Oncol; 2022 Feb; 20(1):46. PubMed ID: 35197061
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma.
Liu EL; Mi RR
Chin Med J (Engl); 2004 Oct; 117(10):1547-51. PubMed ID: 15498381
[TBL] [Abstract][Full Text] [Related]
56. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
57. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
[TBL] [Abstract][Full Text] [Related]
58. [Comparison of postoperative mid-term and long-term quality of life between Billroth-I gastroduodenostomy and Billroth-II gastrojejunostomy after radical distal gastrectomy in patients with gastric cancer: a cohort study based on a case registry database].
Tang KN; Chen XL; Zhang WH; Yang K; Liu K; Jiang W; Chen XZ; Hu JK
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 May; 25(5):401-411. PubMed ID: 35599395
[No Abstract] [Full Text] [Related]
59. Case-mix adjustment to compare hospital performances regarding complications after cytoreductive surgery for ovarian cancer: a nationwide population-based study.
Algera MD; Baldewpersad Tewarie NMS; Driel WJV; van Ham MAPC; Slangen BFM; Kruitwagen RFPM; Wouters MWJM;
Int J Gynecol Cancer; 2023 Apr; 33(4):534-542. PubMed ID: 36581486
[TBL] [Abstract][Full Text] [Related]
60. Beyond post-operative readmissions: analysis of the impact of unplanned readmissions during primary treatment of advanced-stage epithelial ovarian cancer on long-term oncology outcome.
Huang D; Harrison R; Curtis E; Mirabadi N; Chen GY; Alexandridis R; Barroilhet L; Rose S; Hartenbach E; Al-Niami A
Int J Gynecol Cancer; 2023 May; 33(5):741-748. PubMed ID: 36808044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
